Patent details

Basic Information

Publication number:

EP3397281

PCT Application Number:

US2016068847

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP168268654

PCT Publication Number:

WO2017117202

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

BUFFERED FORMULATIONS OF BEVACIZUMAB

French Title of Invention:

FORMULATIONS TAMPONNÉES DE BÉVACIZUMAB

German Title of Invention:

GEPUFFERTE FORMULIERUNGEN VON BEVACIZUMAB

SPC Number:

Dates

Filing date:

28/12/2016

Grant date:

09/09/2020

EP Publication Date:

07/11/2018

PCT Publication Date:

06/07/2017

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

09/09/2020

EP B1 Publication Date:

09/09/2020

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

28/12/2020

Expiration date:

28/12/2036

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

02/09/2020

 

 

Name:

Outlook Therapeutics, Inc.

Address:

7 Clarke Drive, Cranbury, NJ 08512, United States (US)

Inventor

1

Name:

TADDEI, Maria

Address:

United States (US)

2

Name:

CHEUNG, Jessica

Address:

United States (US)

3

Name:

GUTKA, Hiten

Address:

United States (US)

Priority

Priority Number:

201562272116 P

Priority Date:

29/12/2015

Priority Country:

United States (US)

Classification

IPC classification:

A61K 39/395; A61P 35/00; C07K 16/22; C07K 16/24;

Publication

European Patent Bulletin

Issue number:

202037

Publication date:

09/09/2020

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages